Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766397 | 0.82 | CSNK1A1 (0.51) | CSNK1A1CLK4PIN1LRRK2KDM4E | |
| SCHEMBL4765894 | 0.81 | CSNK1A1 (0.50) | CSNK1A1CLK4PIN1LRRK2KDM4E | |
| SCHEMBL21596303 | 0.81 | CSNK1A1 (0.50) | CSNK1A1CLK4PIN1IDH1LRRK2 | |
| SCHEMBL30379868 | 0.81 | CSNK1A1 (0.50) | CSNK1A1CLK4PIN1IDH1LRRK2 | |
| SCHEMBL4770518 | 0.78 | CSNK1A1 (0.47) | CSNK1A1CLK4PIN1LRRK2AURKA | |
| SCHEMBL4768126 | 0.77 | CNR1 (0.46) | CSNK1A1CLK4PIN1LRRK2KDM4E | |
| SCHEMBL3150451 | 0.76 | KMT2A (0.51) | CSNK1A1CLK4PIN1LRRK2CHUK | |
| SCHEMBL30588543 | 0.76 | CSNK1A1 (0.34) | CSNK1A1CLK4PIN1XDHPDE2A | |
| SCHEMBL26125436 | 0.76 | CSNK1A1 (0.34) | CSNK1A1CLK4PIN1XDHPDE2A | |
| SCHEMBL4768640 | 0.76 | POLB (0.49) | CSNK1A1CLK4PIN1LRRK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-2844658-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2844658-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2844652-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2844652-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212186-B2 | Bicyclic pyrazole LRRK2 small molecule inhibitors | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212186-B2 | Bicyclic pyrazole LRRK2 small molecule inhibitors | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (CA) | 2015-02-19 | — | — | US | disclosed |
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1453516-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
| WO-2003032994-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | CSNK1A1 2034/4885CLK4 4753/4885PIN1 1896/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | CSNK1A1 2453/4885CLK4 4758/4885PIN1 648/4885 |
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | CSNK1A1 2158/4885CLK4 412/4885PIN1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.